RCM
IPXL

Riverhead Capital Management’s Impax Laboratories, Inc. IPXL Stock Holding History

Riverhead Capital Management’s Portfolio IPXL Stock Details IPXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-4,384
Closed -$85K – 1599
2018
Q1 		$85K Buy
4,384
+100
+2% +$1.96K ﹤0.01% 1384
2017
Q4 		$71K Buy
4,284
+900
+27% +$16.5K ﹤0.01% 1426
2017
Q3 		$69K Buy
3,384
+321
+10% +$6.14K ﹤0.01% 1387
2017
Q2 		$49K Buy
3,063
+1,463
+91% +$21.6K ﹤0.01% 1416
2017
Q1 		$20K Buy
1,600
+200
+14% +$2.42K ﹤0.01% 1469
2016
Q4 		$19K Hold
1,400
– – ﹤0.01% 1429
2016
Q3 		$33K Sell
1,400
-2,516
-64% -$67.6K ﹤0.01% 1296
2016
Q2 		$364K Sell
3,916
-7,984
-67% -$260K 0.01% 684
2016
Q1 		$381K Sell
11,900
-1,700
-13% -$59.8K 0.01% 996
2015
Q4 		$582K Buy
13,600
+9,900
+268% +$395K 0.01% 829
2015
Q3 		$130K Buy
+3,700
New +$167K ﹤0.01% 931

Riverhead Capital Management's IPXL Position: Q2 2018 in Review

Riverhead Capital Management sold out of Impax Laboratories, Inc. (IPXL) in Q2 2018, closing a stake of 4,384 shares — an estimated $85K sold.

Riverhead Capital Management first reported a position in IPXL in Q3 2015 and held it in 11 quarters. The position peaked at $582K in Q4 2015. 1 fund tracked by Wall St. Rank holds IPXL as of Q2 2018.

  • Riverhead Capital Management reported no remaining Impax Laboratories, Inc. position as of Q2 2018 after selling out during the quarter.
  • Riverhead Capital Management sold 4,384 Impax Laboratories, Inc. shares in Q2 2018, an estimated $85K.
  • Riverhead Capital Management first reported a position in Impax Laboratories, Inc. in Q3 2015 and held it in 11 quarters.
  • Riverhead Capital Management's Impax Laboratories, Inc. position peaked at $582K in Q4 2015.
  • 1 fund tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q2 2018.

Based on Riverhead Capital Management's 13F filing for Q2 2018, filed 10 Aug 2018.